Recruiting × Interventional × Carcinoma, Renal Cell × Clear all Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 Recruiting
314 enrolled
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2 Recruiting
65 enrolled
Keynote B59
Phase 1/2 Recruiting
317 enrolled
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Phase 3 Recruiting
298 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
Phase NA Recruiting
5 enrolled
EXACT
Phase 2 Recruiting
70 enrolled
LITESPARK-033
Phase 3 Recruiting
904 enrolled
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 2 Recruiting
15 enrolled
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase 2 Recruiting
78 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Phase 1 Recruiting
30 enrolled
Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis
Phase NA Recruiting
60 enrolled
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Phase NA Recruiting
410 enrolled
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 Recruiting
125 enrolled
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Phase 1/2 Recruiting
100 enrolled
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Phase 1 Recruiting
307 enrolled
STRIKE
Phase 3 Recruiting
1,040 enrolled
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Phase 2 Recruiting
10 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Phase 1/2 Recruiting
234 enrolled
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/2 Recruiting
75 enrolled
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Phase 1 Recruiting
17 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
LAG-BOOST
Phase 2 Recruiting
72 enrolled
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
ARC-20
Phase 1 Recruiting
362 enrolled
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 2 Recruiting
40 enrolled
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Phase 1 Recruiting
33 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 2 Recruiting
120 enrolled
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Phase 2 Recruiting
55 enrolled
MK-3475-03C
Phase 1/2 Recruiting
140 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 Recruiting
78 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Phase 2 Recruiting
210 enrolled
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Phase 1 Recruiting
174 enrolled
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 Recruiting
60 enrolled
HYPOGRYPHE
Phase NA Recruiting
244 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Phase 2 Recruiting
25 enrolled
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Phase 2 Recruiting
21 enrolled
LN-RCC
Phase NA Recruiting
10 enrolled
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
Phase NA Recruiting
600 enrolled
SKIPPY 2
Phase 2 Recruiting
34 enrolled
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 Recruiting
27 enrolled